A U.K. court has determeind that GSK‘s (GSK) Tesaro will have to pay AstraZeneca (AZN) royalties on total sales of ovarian cancer treatment Zejula, Reuters’ Sinchita Mitra, Ahy Koilparambil, and Yadarisa Shabong report. Tesaro had claimed the royalty was payable only on sales for users claimed or covered by the licensed patents, the authors note. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- Scynexis price target raised to $9 from $8 at Guggenheim
- Liquidia enters new, non-exclusive license agreement with GSK
- ‘Lots to like’ about Scynexis post-Q4, GSK deal, says Cantor Fitzgerald
- GSK, PathAI collaborate on NASH Phase 2b clinical trial
- SCYNEXIS Skyrockets on Teaming Up With GSK for Fungal Treatment